Cargando…

Circulating sclerostin is associated with bone mineral density independent of HIV-serostatus

BACKGROUND: Low bone mineral density (BMD) is commonly observed in people living with HIV (PLWH), however the cause for this BMD loss remains unclear. Sclerostin, a bone-derived antagonist to the Wnt/β-catenin-pathway, suppresses bone remodeling and is positively associated with BMD. The goal of the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ross, Ryan D., Sharma, Anjali, Shi, Qiuhu, Hoover, Donald R., Weber, Kathleen M., Tien, Phyllis C., French, Audrey L., Al-Harthi, Lena, Yin, Michael T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235609/
https://www.ncbi.nlm.nih.gov/pubmed/32455152
http://dx.doi.org/10.1016/j.bonr.2020.100279
_version_ 1783535994814857216
author Ross, Ryan D.
Sharma, Anjali
Shi, Qiuhu
Hoover, Donald R.
Weber, Kathleen M.
Tien, Phyllis C.
French, Audrey L.
Al-Harthi, Lena
Yin, Michael T.
author_facet Ross, Ryan D.
Sharma, Anjali
Shi, Qiuhu
Hoover, Donald R.
Weber, Kathleen M.
Tien, Phyllis C.
French, Audrey L.
Al-Harthi, Lena
Yin, Michael T.
author_sort Ross, Ryan D.
collection PubMed
description BACKGROUND: Low bone mineral density (BMD) is commonly observed in people living with HIV (PLWH), however the cause for this BMD loss remains unclear. Sclerostin, a bone-derived antagonist to the Wnt/β-catenin-pathway, suppresses bone remodeling and is positively associated with BMD. The goal of the current study was to investigate associations between sclerostin and BMD in a cohort of HIV-seropositive and demographically-matched seronegative women. METHODS: This cross-sectional analysis used a subset of early postmenopausal women enrolled in the Women's Interagency HIV Study (WIHS). BMD was assessed at the lumbar spine, total hip, femoral neck, and distal and ultradistal radius via dual energy x-ray absorptiometry (DXA). Circulating sclerostin was assessed via commercial ELISAs. Univariate and multivariate linear regression modeling tested associations between sclerostin and BMD after adjusting for a variety of BMD-modifying variables. RESULTS: HIV-seropositive women had significantly reduced BMD at all skeletal sites compared to HIV-seronegative women. There was no difference in sclerostin levels according to HIV-serostatus (0.25 vs 0.27 ng/mL in HIV-seronegative and HIV-seropositive, respectively, p = 0.71). Circulating sclerostin was positively associated with BMD at all sites in both univariate and multivariate models adjusting for HIV status, age, BMI, and race, although the coefficients of association were attenuated in HIV-seropositive women. The positive association between sclerostin and BMD among seropositive women remained statistically significant after adjusting for ART or tenofovir disoproxil fumarate (TDF) use. CONCLUSIONS: The current study suggests that circulating sclerostin is a biomarker for bone mass for both HIV seronegative and seropositive women using and not using ART. The lower coefficients of association between sclerostin and BMD by HIV status may suggest HIV-induced alternation in osteocyte function.
format Online
Article
Text
id pubmed-7235609
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-72356092020-05-22 Circulating sclerostin is associated with bone mineral density independent of HIV-serostatus Ross, Ryan D. Sharma, Anjali Shi, Qiuhu Hoover, Donald R. Weber, Kathleen M. Tien, Phyllis C. French, Audrey L. Al-Harthi, Lena Yin, Michael T. Bone Rep Article BACKGROUND: Low bone mineral density (BMD) is commonly observed in people living with HIV (PLWH), however the cause for this BMD loss remains unclear. Sclerostin, a bone-derived antagonist to the Wnt/β-catenin-pathway, suppresses bone remodeling and is positively associated with BMD. The goal of the current study was to investigate associations between sclerostin and BMD in a cohort of HIV-seropositive and demographically-matched seronegative women. METHODS: This cross-sectional analysis used a subset of early postmenopausal women enrolled in the Women's Interagency HIV Study (WIHS). BMD was assessed at the lumbar spine, total hip, femoral neck, and distal and ultradistal radius via dual energy x-ray absorptiometry (DXA). Circulating sclerostin was assessed via commercial ELISAs. Univariate and multivariate linear regression modeling tested associations between sclerostin and BMD after adjusting for a variety of BMD-modifying variables. RESULTS: HIV-seropositive women had significantly reduced BMD at all skeletal sites compared to HIV-seronegative women. There was no difference in sclerostin levels according to HIV-serostatus (0.25 vs 0.27 ng/mL in HIV-seronegative and HIV-seropositive, respectively, p = 0.71). Circulating sclerostin was positively associated with BMD at all sites in both univariate and multivariate models adjusting for HIV status, age, BMI, and race, although the coefficients of association were attenuated in HIV-seropositive women. The positive association between sclerostin and BMD among seropositive women remained statistically significant after adjusting for ART or tenofovir disoproxil fumarate (TDF) use. CONCLUSIONS: The current study suggests that circulating sclerostin is a biomarker for bone mass for both HIV seronegative and seropositive women using and not using ART. The lower coefficients of association between sclerostin and BMD by HIV status may suggest HIV-induced alternation in osteocyte function. Elsevier 2020-05-11 /pmc/articles/PMC7235609/ /pubmed/32455152 http://dx.doi.org/10.1016/j.bonr.2020.100279 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Ross, Ryan D.
Sharma, Anjali
Shi, Qiuhu
Hoover, Donald R.
Weber, Kathleen M.
Tien, Phyllis C.
French, Audrey L.
Al-Harthi, Lena
Yin, Michael T.
Circulating sclerostin is associated with bone mineral density independent of HIV-serostatus
title Circulating sclerostin is associated with bone mineral density independent of HIV-serostatus
title_full Circulating sclerostin is associated with bone mineral density independent of HIV-serostatus
title_fullStr Circulating sclerostin is associated with bone mineral density independent of HIV-serostatus
title_full_unstemmed Circulating sclerostin is associated with bone mineral density independent of HIV-serostatus
title_short Circulating sclerostin is associated with bone mineral density independent of HIV-serostatus
title_sort circulating sclerostin is associated with bone mineral density independent of hiv-serostatus
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7235609/
https://www.ncbi.nlm.nih.gov/pubmed/32455152
http://dx.doi.org/10.1016/j.bonr.2020.100279
work_keys_str_mv AT rossryand circulatingsclerostinisassociatedwithbonemineraldensityindependentofhivserostatus
AT sharmaanjali circulatingsclerostinisassociatedwithbonemineraldensityindependentofhivserostatus
AT shiqiuhu circulatingsclerostinisassociatedwithbonemineraldensityindependentofhivserostatus
AT hooverdonaldr circulatingsclerostinisassociatedwithbonemineraldensityindependentofhivserostatus
AT weberkathleenm circulatingsclerostinisassociatedwithbonemineraldensityindependentofhivserostatus
AT tienphyllisc circulatingsclerostinisassociatedwithbonemineraldensityindependentofhivserostatus
AT frenchaudreyl circulatingsclerostinisassociatedwithbonemineraldensityindependentofhivserostatus
AT alharthilena circulatingsclerostinisassociatedwithbonemineraldensityindependentofhivserostatus
AT yinmichaelt circulatingsclerostinisassociatedwithbonemineraldensityindependentofhivserostatus